NDA 020287 · Pfizer
Fragmin
Dalteparin Sodium · Injection, Subcutaneous
NovelLast checked: Nov 20, 2026Latest source record: Oct 24, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Dec 22, 1994
Approved uses
8
Original approval plus efficacy supplements
Registered trials
664
227 Phase 3, 66 recruiting
FAERS reports
10,659
9,759 serious, 2,313 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • Use of indwelling epidural catheters • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants. • A history of traumatic or repeated epidural or spinal punctures • A history of spinal deformity or spinal surgery • Optimal timing between the administration of FRAGMIN and neuraxial procedures is not known Monitor patients...
What it is approved for
From the label in effect Sep 30, 2025.
FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) 1.1 Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction FRAGMIN Injection is indicated for the prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin therapy [see Clinical Studies (14.1) ] . 1.2 Prophylaxis of Deep Vein Thrombosis FRAGMIN is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): • In patients undergoing hip replacement surgery [see Clinical Studies (14.2) ] ; • In patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.3) ] ; • In medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness [see Clinical Studies (14.4) ] . 1.3 Extended Treatment of Symptomatic Venous Thromboembolism (VTE) in Adult Patients with Cancer FRAGMIN is indicated for the extended...
Mechanism: Dalteparin is a low molecular weight heparin with antithrombotic properties. It acts by enhancing the inhibition of Factor Xa and thrombin by antithrombin. In humans, dalteparin potentiates preferentially the inhibition of coagulation Factor Xa, while only slightly affecting the activated partial thromboplastin time (APTT).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 15, 2024 Supplement 80 · Efficacy LetterLabel
- May 16, 2019 Supplement 72 · Efficacy · priority review LabelLetterPediatric Other
- May 1, 2007 Supplement 35 · Efficacy ReviewLetterLabel
- Dec 10, 2003 Supplement 32 · Efficacy ReviewLetterLabel
- May 25, 1999 Supplement 10 · Efficacy ReviewLetterLabel
- Mar 30, 1999 Supplement 8 · Efficacy ReviewLetterLabel
- Mar 18, 1996 Supplement 3 · Efficacy
- Dec 22, 1994 Original approval · Type 1 - New Molecular Entity
12 products under this application
- FRAGMIN · DALTEPARIN SODIUM 7,500 IU/0.75ML · INJECTABLE, INJECTION · Discontinued
- FRAGMIN · DALTEPARIN SODIUM 95,000IU/3.8ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
- FRAGMIN · DALTEPARIN SODIUM 10,000IU/4ML (2,500IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
- FRAGMIN · DALTEPARIN SODIUM 10,000IU/ML (10,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
- FRAGMIN · DALTEPARIN SODIUM 15,000IU/0.6ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
- FRAGMIN · DALTEPARIN SODIUM 10,000IU/0.4ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
- FRAGMIN · DALTEPARIN SODIUM 12,500IU/0.5ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
- FRAGMIN · DALTEPARIN SODIUM 95,000IU/9.5ML (10,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Discontinued
- FRAGMIN · DALTEPARIN SODIUM 7,500IU/0.3ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
- FRAGMIN · DALTEPARIN SODIUM 18,000IU/0.72ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
- FRAGMIN · DALTEPARIN SODIUM 5,000IU/0.2ML (25,000IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
- FRAGMIN · DALTEPARIN SODIUM 2,500IU/0.2ML (12,500IU/ML) · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dalteparin" as an intervention, any sponsor and status, largest first.
- Study of Low Molecular Weight HeparinsPivotal-lookingStatus unknown
Herlev HospitalAcademic, hospital or other
NCT06020560 · 65,000 participants (planned) · Start Mar 23, 2023 · Primary completion Mar 23, 2025
Drug: Dalteparin Prefilled Syringe; Tinzaparin profiled syringe · For: Anticoagulant; Venous Thromboembolism; Prophylaxis and 1 more
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 9 sites in all
- Delivery and Implementation of a Randomised Crossover Trial on ThrombosisPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06937372 · 21,194 participants (planned) · Start Jul 1, 2026 · Primary completion Oct 31, 2027
Drug: Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.; Low molecular weight heparin (LMWH) · For: Hip Fractures; Venous Thromboembolism (VTE)
Sites: London, United Kingdom
- Michelangelo - Oasis 5Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00139815 · 20,078 participants · Start Apr 2003 · Primary completion Dec 2005
Drug: Fondaparinux; enoxaparin · For: Thromboembolism
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- PREVENTion of Clot in Orthopaedic TraumaPivotal-lookingCompleted
Major Extremity Trauma Research ConsortiumAcademic, hospital or other
NCT02984384 · 12,424 participants · Start Apr 24, 2017 · Primary completion Feb 18, 2022
Drug: Acetylsalicylic acid; Low Molecular Weight Heparin (LMWH) · For: Blood Clot; Trauma
Sites: Tucson, Arizona; Miami, Florida; Indianapolis, Indiana · 21 sites in all
- Thromboprophylaxis in Lower Limb ImmobilisationPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06370273 · 10,044 participants (planned) · Start Nov 12, 2024 · Primary completion Aug 31, 2028
Drug: Rivaroxaban; Apixaban and 4 more · For: Thrombosis; Injury Leg
Sites: Carshalton, United Kingdom; Hull, United Kingdom; London, United Kingdom · 5 sites in all
- The Intensive Care Platform TrialPivotal-lookingRecruiting
Anders PernerAcademic, hospital or other
NCT06667999 · 10,000 participants (planned) · Start Jun 26, 2025 · Primary completion Dec 2035
Drug: Albumin; LMWH in weight-adjusted dose and 2 more · For: Intensive Care Patients; Intensive Care Unit Patients; Critical Illness
Sites: Vienna, Austria; Aabenraa, Denmark; Aalborg, Denmark · 40 sites in all
- EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00089895 · 9,406 participants · Start Nov 1, 2004 · Primary completion Nov 1, 2008
Drug: Eptifibatide (Integrilin); Placebo · For: Myocardial Ischemia; Acute Coronary Syndrome
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea720
- off label use714
- pulmonary embolism618
- dyspnoea603
- vomiting586
- abdominal pain537
- sepsis513
- pyrexia501
- general physical health deterioration477
- diarrhoea461
- fatigue461
- anaemia458
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 192 |
| 2005 | 182 |
| 2006 | 205 |
| 2007 | 233 |
| 2008 | 219 |
| 2009 | 339 |
| 2010 | 399 |
| 2011 | 505 |
| 2012 | 572 |
| 2013 | 390 |
| 2014 | 442 |
| 2015 | 477 |
| 2016 | 522 |
| 2017 | 472 |
| 2018 | 607 |
| 2019 | 641 |
| 2020 | 640 |
| 2021 | 859 |
| 2022 | 710 |
| 2023 | 667 |
| 2024 | 542 |
| 2025 | 446 |
| 2026 | 396 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fragmin (Dalteparin Sodium,Porcine)
2024 spending
$1.8M
Beneficiaries
82
421 claims
Per beneficiary
$22,161
$246.71 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,037,449 |
| 2021 | $2,351,703 |
| 2022 | $1,939,380 |
| 2023 | $2,204,099 |
| 2024 | $1,817,234 |
Part B: Fragmin (Dalteparin Sodium,porcine) · HCPCS J1645
2024 spending
$12K
Beneficiaries
20
155 claims
Per beneficiary
$577
2024 ASP limit $16.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $66,328 |
| 2021 | $25,496 |
| 2022 | $18,280 |
| 2023 | $17,248 |
| 2024 | $11,544 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 3-Defining antithrombotic protocols.
Blais MC, Bianco D, Goggs R, et al. · J Vet Emerg Crit Care (San Antonio) 2019 · Consensus Statement, Practice Guideline
- Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Agnelli G, Becattini C, Meyer G, et al. · N Engl J Med 2020 · Equivalence Trial, Multicenter Study
- Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review.
Abildgaard A, Madsen SA, Hvas AM · Semin Thromb Hemost 2020 · Systematic Review
- Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Raskob GE, van Es N, Verhamme P, et al. · N Engl J Med 2018 · Equivalence Trial, Randomized Controlled Trial
- Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
McBane RD, Wysokinski WE, Le-Rademacher JG, et al. · J Thromb Haemost 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.
Douketis JD, Spyropoulos AC, Kaatz S, et al. · N Engl J Med 2015 · Multicenter Study, Randomized Controlled Trial
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.